News & Events
News & Events
October 28, 2020
C-Path and EATRIS To Collaborate on RDCA-DAP
C-Path has signed a Memorandum of Understanding with EATRIS, the European infrastructure for translational medicine, to accelerate drug development for rare diseases by increasing the efficiency of translation of potential therapeutics through preclinical and clinical development …
July 14, 2020
C-Path Data Collaboration Center Analytics Team Wins Metadata Automation DREAM ChallengeTUCSON, Ariz., July 14, 2020 — Tucson-based Critical Path Institute (C-Path) today proudly announced that the analytics team from its Data Collaboration Center (DCC) program has won first place in the validation phase of the Metadata Automation DREAM Challenge, funded by the Cancer Moonshot℠ initiative. The mission of C-Path’s DCC program is to provide large-scale data collaboration...
December 2, 2019
Workshop Summary, Advancing the Development and Implementation of Analysis Data Standards, Now AvailableC-Path is proud to announce the availability of the workshop summary, Advancing the Development and Implementation of Analysis Data Standards: Key Challenges and Opportunities. The workshop, in collaboration with the Duke-Margolis Center for Health Policy and the Food and Drug Administration (FDA), was planned with the support of C-Path data standard expertise, and included a...
October 15, 2019
C-Path, CDISC Develop Standard to Represent Data for Animal Rule Studies
C-Path and CDISC are pleased to announce the release of a global Foundational Standard that describes how to represent data for the natural history and efficacy studies conducted in animals submitted to applications under the U.S. Food and Drug Administration (FDA) regulations commonly known as the Animal Rule.
August 7, 2019
Funded by FDA, C-Path and NORD to Launch Rare Disease Data and Analytics Platform
C-Path and NORD Rare Disease Cures Accelerator Data Analytics Platform Launch, Tuesday, Sept. 17, Bethesda, MD
C-Path and the National Organization for Rare Disorders® will host a meeting to formally launch development of a new rare disease data and analytics platform. Funded by a cooperative agreement through the U.S. Food and Drug Administration, the goal of the platform is to accelerate the movement of therapies from bench to bedside for rare diseases. Register here.